GlassScriptPhysician profile
Tamer Dafashy
NPI 1235669276
$6,077.39
in general payments reported to CMS, 2019-2025
33 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $107 · 2021: $140 · 2022: $1,704 · 2023: $1,432 · 2024: $1,205 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.17 |
| Education | $120.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,144.20 | 2019-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $968.39 | 2019-2025 | Axonics, Rezum Generator, Spaceoar Vue System - 10ml |
| Coloplast Corp | $603.89 | 2021-2025 | Porges Coloplast, Titan |
| Astellas Pharma US INC | $492.82 | 2019-2024 | Myrbetriq, Xtandi |
| Axonics, INC. | $445.34 | 2022-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $267.77 | 2022-2025 | Interstim |
| Sumitomo Pharma America, INC. | $265.21 | 2023-2025 | Gemtesa |
| Endo Pharmaceuticals INC. | $242.12 | 2020-2023 | Aveed, Xiaflex |
| Myriad Genetic Laboratories, INC. | $183.41 | 2023-2024 | Prolaris, Bracanalysis Cdx |
| Ethicon US, LLC | $170.25 | 2021-2024 | Enseal X1, Echelon Flex, Vistaseal |
| Antares Pharma, INC. | $164.52 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Intuitive Surgical, INC. | $157.99 | 2024 | |
| Neotract INC. | $118.63 | 2019 | |
| Merck Sharp & Dohme LLC | $106.55 | 2023-2024 | Keytruda, Lenvima, Welireg |
| Olympus America INC. | $82.71 | 2022-2024 | Itind System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $72.93 | 2023 | |
| Ferring Pharmaceuticals INC. | $63.08 | 2024-2025 | Adstiladrin |
| Pfizer INC. | $57.45 | 2025 | |
| Healthtronics Stone Solutions, LLC | $56.59 | 2020 | |
| Verity Pharmaceuticals INC. | $52.79 | 2025 | Trelstar |
| Urovant Sciences INC | $44.00 | 2022 | |
| Abbvie INC. | $43.76 | 2022-2023 | Botox |
| Endo USA, INC. | $37.93 | 2024 | Aveed, Xiaflex |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Tolmar, INC. | $32.10 | 2025 | Eligard, Jatenzo |
| Argon Medical Devices, INC. | $31.68 | 2024 | Clot Management |
| Urogen Pharma, INC. | $25.11 | 2024 | |
| Procept Biorobotics Corporation | $23.47 | 2022 | |
| Integra Lifesciences Corporation | $19.54 | 2024 | Codman Hakim, Codman Certas, Cusa Clarity |
| Laborie Medical Technologies Corp. | $17.94 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| 180 Medical, INC. | $17.20 | 2023 | |
| Civco Medical Instruments | $17.00 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $15.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamer Dafashy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.